{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:04:09Z","timestamp":1772237049663,"version":"3.50.1"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.2169\/internalmedicine.7291-21","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T18:08:28Z","timestamp":1635703708000},"page":"3359-3368","source":"Crossref","is-referenced-by-count":8,"title":["Serum Copeptin and Zinc-\u03b12-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites"],"prefix":"10.2169","volume":"60","author":[{"given":"Ryuta","family":"Shigefuku","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoh","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Tempaku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Tamai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bolignano D, Cabassi A, Fiaccadori E, et al. Copeptin (ctproavp), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med 52: 1447-1456, 2014.","DOI":"10.1515\/cclm-2014-0379"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112-119, 2006.","DOI":"10.1373\/clinchem.2005.060038"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kerbert AJC, Weil D, Verspaget HW, et al. Copeptin is an independent prognostic factor for transplant-free survival in cirrhosis. Liver Int 36: 530-537, 2015.","DOI":"10.1111\/liv.12992"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sol\u00e0 E, Kerbert AJ, Verspaget HW, et al. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. J Hepatol 65: 914-920, 2016.","DOI":"10.1016\/j.jhep.2016.07.003"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Shigefuku R, Iwasa M, Eguchi A, et al. Serum copeptin level is a biomarker associated with ascites retention and the formation of a portosystemic shunt in chronic liver disease. J Gastroenterol Hepatol 36: 1006-1014, 2021.","DOI":"10.1111\/jgh.15215"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bouchara A, Yi D, Pastural M, et al. Serum levels of the adipokine zinc-alpha2-glycoprotein (ZAG) predict mortality in hemodialysis patients. Kidney Int 94: 983-992, 2018.","DOI":"10.1016\/j.kint.2018.07.019"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365: 1231-1238, 2005.","DOI":"10.1016\/S0140-6736(05)74811-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115: 610-621, 2005.","DOI":"10.1172\/JCI23056"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ichikawa D, Kamijo-Ikemori A, Sugaya T, et al. Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion. Nephrology (Carlton) 23: 308-316, 2018.","DOI":"10.1111\/nep.12998"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yoshikawa K, Iwasa M, Eguchi A, et al. Neutrophil gelatinase-associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases. Hepatol Commun 1: 946-956, 2017.","DOI":"10.1002\/hep4.1109"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Eguchi A, Hasegawa H, Iwasa M, et al. Serum liver-type fatty acid-binding protein is a possible prognostic factor in human chronic liver diseases from chronic hepatitis to liver cirrhosis and hepatocellular carcinoma. Hepatol Commun 3: 825-837, 2019.","DOI":"10.1002\/hep4.1350"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kawaratani H, Fukui H, Moriya K, et al. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. Hepatol Res 47: 854-861, 2017.","DOI":"10.1111\/hepr.12826"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bellos I, Kontzoglou K, Perrea DN. Predictors of tolvaptan short-term response in patients with refractory ascites: a meta-analysis. J Gastroenterol Hepatol 35: 182-191, 2020.","DOI":"10.1111\/jgh.14784"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Atsukawa M, Tsubota A, Takaguchi K, et al. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. J Gastroenterol Hepatol 35: 1229-1237, 2020.","DOI":"10.1111\/jgh.14965"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bellos I, Kontzoglou K, Psyrri A, Pergialiotis V. Tolvaptan response improves overall survival in patients with refractory ascites: a meta-analysis. Dig Dis 38: 320-328, 2020.","DOI":"10.1159\/000503559"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 51: 629-650, 2016.","DOI":"10.1007\/s00535-016-1216-y"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hiramine Y, Uojima H, Nakanishi H, et al. Response criteria of tolvaptan for the treatment of hepatic edema. J Gastroenterol 53: 258-268, 2018.","DOI":"10.1007\/s00535-017-1366-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33: 550-558, 2015.","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43: 1317-1325, 2006.","DOI":"10.1002\/hep.21178"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Moller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 38: 570-580, 2018.","DOI":"10.1111\/liv.13589"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151-1157, 1988.","DOI":"10.1002\/hep.1840080532"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. P\u00e9rez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis Kidney Int. 26: 72-80, 1984.","DOI":"10.1038\/ki.1984.136"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Belcher JM, Parikh CR, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol 11: 1550-1558, 2013.","DOI":"10.1016\/j.cgh.2013.03.018"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Allegretti AS, Sol\u00e0 E, Gin\u00e8s P. Clinical application of kidney biomarkers in cirrhosis. Am J Kidney Dis 76: 710-719, 2020.","DOI":"10.1053\/j.ajkd.2020.03.016"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sorensen-Zender I, Beneke J, Schmidt BM, Menne J, Haller H, Schmitt R. Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease. BMC Nephrol 14: 145, 2013.","DOI":"10.1186\/1471-2369-14-145"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lim SC, Liying DQ, Toy WC, et al. Adipocytokine zinc alpha2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy. Diabet Med 29: 945-949, 2012.","DOI":"10.1111\/j.1464-5491.2011.03564.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Batista ML Jr, Olivan M, Alcantara PSM, et al. Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. Cytokine 61: 532-539, 2013.","DOI":"10.1016\/j.cyto.2012.10.023"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Bing C, Trayhurn P. New insights into adipose tissue atrophy in cancer cachexia. Proc Natl Acad Sci U S A 68: 385-392, 2009.","DOI":"10.1017\/S0029665109990267"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Nakai M, Ogawa K, Takeda R, et al. Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. Hepatol Res 48: E311-E319, 2018.","DOI":"10.1111\/hepr.12988"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sakaida I, Terai S, Kurosaki M, Okada M, Hirano T, Fukuta Y. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (start study). J Gastroenterol 55: 800-810, 2020.","DOI":"10.1007\/s00535-020-01691-x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_7291-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T20:11:00Z","timestamp":1699733460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_7291-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":30,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7291-21","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-52252\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-52252\/v1","asserted-by":"object"}]},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"7291-21"}}